Citi initiated coverage of Alpha Tau Medical with a Buy rating and $8 price target. The analyst says Alpha Tau is an “innovative” radiotherapy company focused on developing its Alpha DaRT technology for use in cancer. With significant proof-of-concept already established in a range of tumor types, Citi sees potentially many applications for this technology emerging over the next several years, the analyst tells investors in a research note. The fir says near-term upside could be driven by pivotal data in 2024 from the ReSTART study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DRTS:
- Alpha Tau to Participate in Sidoti Small-Cap Conference
- Alpha Tau reports interim results from trial of Alpha DaRT treatment
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau submits to Japanese PMDA for pre-market approval of Alpha DaRT
